Metabolic parameters in patients treated with olanzapine or other atypical antipsychotics

Journal of Psychopharmacology

Volumn 25, Issue 5, 2011, Pages 630-638

  Osuntokun, Olawale ^a   Millen, Brian ^a   Xu, Wen I ^a   Kryzhanovskaya, Ludmilla A ^a   Robertson Plouch, Carol ^a   Carlson, Janice L ^a   Acharya, Nayan ^a   Corya, Sara A ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

aripirazole; cholesterol; clozapine; glucose; olanzapine; quetiapine; risperidone; triglycerides; weight; ziprasidone

Indexed keywords

ARIPIPRAZOLE; CLOZAPINE; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; DRUG WITHDRAWAL; GLUCOSE BLOOD LEVEL; HUMAN; IMPAIRED GLUCOSE TOLERANCE; METABOLIC PARAMETERS; PRIORITY JOURNAL; SCHIZOPHRENIA; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BLOOD GLUCOSE; DATABASES, FACTUAL; FEMALE; HUMANS; MALE; RISK; TRIGLYCERIDES; WEIGHT GAIN;

EID: 79955436769     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881110368872     Document Type: Article

References (17)

1. Allison DB, Casey DE. Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry. 2001 ; 62 (Suppl 7). 22-31 (Pubitemid 32402182)
2. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004 ; 27: 596-601
3. Deberdt W, Lipkovich I, Heinloth AN, et al. Double-blind, randomized trial comparing efficacy and safety of continuing olanzapine versus switching to quetiapine in overweight or obese patients with schizophrenia or schizoaffective disorder. Ther Clin Risk Manag. 2008 ; 4: 713-720
4. Hardy TA, Marquez E, Kryzhanovskaya L, Taylor CC, Cavazzoni P. Cross-sectional comparison of fasting lipids in normoglycemic patients with schizophrenia during chronic treatment with olanzapine, risperidone, or typical antipsychotics. J Clin Psychopharmacol. 2006 ; 26: 405-408 (Pubitemid 44187644)
5. Henderson DC. Weight gain with atypical antipsychotics: evidence and insights. J Clin Psychiatry. 2007 ; 68 (Suppl 12). 18-26 (Pubitemid 350021619)
6. Henderson DC, Cagliero E, Copeland PM, et al. Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis. Arch Gen Psychiatry. 2005 ; 62: 19-28 (Pubitemid 40096067)
7. Henderson DC, Copeland PM, Borba CP, et al. Glucose metabolism in patients with schizophrenia treated with olanzapine or quetiapine: a frequently sampled intravenous glucose tolerance test and minimal model analysis. J Clin Psychiatry. 2006 ; 67: 789-797 (Pubitemid 43946186)
8. Kelly DL, Kreyenbuhl J, Love RC, Van-Duong Q, Conley RR. Six-month review of weight and metabolic parameters in patients receiving clozapine, risperidone, olanzapine, or quetiapine. J Clin Psychiatry. 2003 ; 64: 1133-1134 (Pubitemid 37158264)
9. Kinon BJ, Volavka J, Stauffer V, et al. Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder. J Clin Psychopharmacol. 2008 ; 28: 392-400
10. Lieberman JA, Stroup TS, McEvoy JP, et al. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005 ; 353: 1209-1223
11. Lindenmayer JP, Czobor P, Volavka J, et al. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry. 2003 ; 160: 290-296 (Pubitemid 41110454)
12. McEvoy JP, Lieberman JA, Perkins DO, et al. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry. 2007 ; 164: 1050-1060 (Pubitemid 47121394)
13. McIntyre RS, Trakas K, Lin D, et al. Risk of weight gain associated with antipsychotic treatment: results from the Canadian National Outcomes Measurement Study in Schizophrenia. Can J Psychiatry. 2003 ; 48: 689-694 (Pubitemid 37522542)
14. Meltzer HY, Bobo WV, Roy A, et al. A randomized, double-blind comparison of clozapine and high-dose olanzapine in treatment-resistant patients with schizophrenia. J Clin Psychiatry. 2008 ; 69: 274-285 (Pubitemid 351469271)
15. Meyer JM, Koro CE. The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophr Res. 2004 ; 70: 1-17 (Pubitemid 38916622)
16. Sacchetti E, Valsecchi P, Parrinello G, QUERISOLA Group. A randomized, flexible-dose, quasi-naturalistic comparison of quetiapine, risperidone, and olanzapine in the short-term treatment of schizophrenia: The QUERISOLA trial. Schizophr Res. 2008 ; 98: 55-65 (Pubitemid 350245584)
17. Smith RC, Lindenmayer JP, Bark N, Warner-Cohen J, Vaidhyanathaswamy S, Khandat A. Clozapine, risperidone, olanzapine, and conventional antipsychotic drug effects on glucose, lipids, and leptin in schizophrenic patients. Int J Neuropsychopharmacol. 2005 ; 8: 183-194